Peptides for Dry Eye & Ocular-Surface Repair: The Honest Evidence Review

RGN-259 is a preservative-free, sterile topical ophthalmic solution of synthetic full-length thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid actin-sequestering peptide whose best-characterized ocular action is promoting corneal epithelial cell migration and wound closure, alongside cytoprotective and anti-inflammatory effects. It is the single genuine exception to the usual peptide pattern for the eye: rather than resting on animal data, Tβ4 has been tested in multiple large, randomized, double-masked, placebo-controlled human trials, including the three-trial ARISE Phase 3 dry-eye program (roughly 1,500 to 1,600 patients) and Phase 3 neurotrophic-keratopathy trials (SEER-1, SEER-3). The honest headline is that every pivotal Phase 3 missed its pre-specified co-primary endpoint — ARISE-1, ARISE-2, ARISE-3 for dry eye and the European SEER-3 for neurotrophic keratitis. What the program did show repeatedly is statistically significant improvement on numerous secondary endpoints: reduced corneal fluorescein staining, less ocular discomfort, and reduced grittiness, with pooled central corneal staining significant across the three ARISE trials. Safety was excellent across more than 1,700 treated subjects, with no signal on intraocular pressure, visual acuity, or corneal sensitivity. It earns Grade B — real human RCT evidence and a consistent benefit signal, but no clean confirmatory win and no FDA approval.

Best for

Understanding the strongest human peptide evidence for the ocular surface — and its unproven-on-the-strict-endpoint limit

Pricing

Investigational / not approved

Source: ReGenTree pooled ARISE Phase 3 dry-eye results (2021)

Cenegermin-bkbj (Oxervate) is included here as the evidentiary benchmark, not as a wellness peptide. It is a recombinant human nerve growth factor — a biologic protein, not a short synthetic peptide bought online — delivered as an eye drop and FDA-approved on August 22, 2018 for neurotrophic keratitis. Its approval rests on a clean pivotal program: 151 patients across two eight-week randomized controlled trials in which roughly 70 percent of cenegermin-treated eyes achieved complete corneal healing versus about 28 percent on vehicle. That is the kind of controlled human outcome data, on a pre-specified endpoint, that the peptide candidates for dry eye do not have. The critical caveats are its indication and its nature. Cenegermin is approved for neurotrophic keratitis — a specific corneal denervation disorder — and not for ordinary dry eye disease, so it is not a general dry-eye therapy. It is also a prescription recombinant-protein biologic obtained through a specialist and specialty pharmacy, with a notable cost, rather than a peptide sold as a supplement or research chemical. It ranks second here precisely because it shows what Grade-A ocular-surface regeneration evidence looks like, setting the bar the dry-eye peptides have not yet cleared.

Best for

Seeing what an FDA-approved, RCT-proven ocular-surface repair drug looks like (neurotrophic keratitis, not dry eye)

Pricing

Prescription biologic; high cost

Source: AAO — FDA approves first neurotrophic keratitis drug (cenegermin), 2018

This entry is not a peptide — it is the honest first-line benchmark every peptide above is measured against. Dry eye disease is a chronic, multifactorial disorder of the tear film and ocular surface driven by tear instability, hyperosmolarity, inflammation, and epithelial damage, and the interventions with the strongest and most accessible human evidence target exactly those mechanisms. Approved pharmacologic options act mainly on inflammation or tear production — including topical immunomodulators such as cyclosporine and lifitegrast — and are backed by controlled human trials and regulatory approval, unlike the peptide candidates. Alongside them sit tear-film support (preservative-free artificial tears), lid-margin and meibomian-gland management, and treatment of the underlying drivers a functional, root-cause assessment would surface, from environmental and screen-time factors to systemic and hormonal contributors. Notably, the one peptide with human data, RGN-259, was benchmarked against cyclosporine, diquafosol, and lifitegrast in a mouse model — a preclinical comparison, not a human head-to-head — so any claim that the peptide matches or beats approved drugs in patients is unsupported. Included at rank 3 to keep the comparison honest: this is where an eye specialist actually starts, and it is graded A because it rests on controlled human evidence and real-world outcomes rather than extrapolation.

Best for

Anyone with dry eye seeking the evidence-based standard of care while peptide options remain investigational

Pricing

Clinical care; varies

Source: Kim et al., Sci Rep 2018 (RGN-259 vs approved drugs, mouse model — preclinical comparison only)

TB-500 is a synthetic peptide corresponding to the actin-binding region (residues roughly 17 to 23) of thymosin beta-4, sold for systemic injection as a healing and recovery peptide. For dry eye and ocular-surface repair it earns Grade D because it has no human or animal dry-eye or ocular-surface efficacy evidence whatsoever, and it is not formulated, sterilized, or studied as an eye treatment. The marketing sleight of hand is the conflation of TB-500 with RGN-259: the two are different things. RGN-259 is a sterile, preservative-free topical eye drop of the full-length 43-amino-acid molecule, tested in large eye trials, whereas TB-500 is a roughly seven-amino-acid injectable fragment with an entirely different route and no eye data. Any claim that injected TB-500 treats dry eye is unproven marketing that borrows credibility from the unrelated ophthalmic program. Beyond the absence of evidence, TB-500 carries its own regulatory and anti-doping baggage: it is not FDA-approved for any human use, sits as a 503A Category 2 bulk substance not endorsed for routine compounding as of early 2026, and both TB-500 and thymosin beta-4 are prohibited at all times under the WADA Prohibited List regardless of route, amount, or timing. Applying a non-sterile, grey-market injectable to the eye would also introduce a serious infection risk. It ranks last precisely because it is the most-hyped and least-supported option for this indication.

Best for

Recognizing the widest promise-versus-proof gap in the dry-eye peptide category — a cautionary contrast, not a therapy

Pricing

Research chemical / unapproved

Source: BSCG — TB-500 status, risks and bans in sport and military (2026)

A recurring online claim is that injectable systemic 'healing' peptides — most often BPC-157, sometimes bundled with TB-500 — can be used to heal the eyes or treat dry eye. This category earns Grade D for the ocular surface because there is no ocular-surface trial evidence for systemic peptide injections in dry eye, full stop. The claim borrows credibility from the genuinely tested topical program (RGN-259) while quietly swapping in a completely different molecule, route, and formulation: a systemic injectable sold as a research chemical is not a sterile ophthalmic solution, and no dry-eye or corneal-repair human data support it. The regulatory picture reinforces the caution. These peptides are not FDA-approved for any human use, several were caught up in the FDA's 503A Category 2 bulk-substance actions with a Pharmacy Compounding Advisory Committee review actively in flux in 2026, and thymosin beta-4 and TB-500 are prohibited at all times under the WADA Prohibited List. There is also a distinct safety problem specific to the eye: applying non-sterile, grey-market material anywhere near the ocular surface risks microbial keratitis and sight-threatening infection, because the cornea has essentially no margin for contamination. This entry ranks last because it pairs zero relevant evidence with real regulatory and safety hazards — it is included to name and debunk a common marketing claim, not to endorse it.

Best for

Debunking the 'inject peptides to heal your eyes' claim — a cautionary contrast, not a therapy

Pricing

Research chemical / unapproved

Source: FDA Law Blog — FDA peptide compounding / 503A bulk substances (2026)